Company intelligence / Profile preview
Pulmocide
London, England, United Kingdompulmocide.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pulmocide’s lead asset, opelconazole, an inhaled antifungal azole, has shown promising results as both treatment and prophylaxis for serious Aspergillus-related lung diseases. It has been generally well tolerated in clinical studies and received multiple FDA designations to expedite development. The company’s pipeline also includes PC786, an antiviral targeting RSV.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small molecules (inhaled azole antifungals and antivirals)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Pulmocide.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pulmocide.